Nitroxazepine (brand name Sintamil) is a tricyclic antidepressant (TCA) which was introduced by Ciba-Geigy (now Novartis) for the treatment of depression in India in 1982.[1] It is also indicated for the treatment of nocturnal enuresis.[1] Nitroxazepine acts as a serotonin-norepinephrine reuptake inhibitor and has similar effects to imipramine, but with certain advantages, such as lower anticholinergic side effects.[2][3][4]
Clinical data | |
---|---|
Trade names | Sintamil |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEBI |
|
Chemical and physical data | |
Formula | C18H19N3O4 |
Molar mass | 341.367 g·mol−1 |
3D model (JSmol) |
|
| |
|